X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Piramal Healthcare with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs SUN PHARMA - Comparison Results

PIRAMAL ENTERPRISES    Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES SUN PHARMA PIRAMAL ENTERPRISES/
SUN PHARMA
 
P/E (TTM) x 36.6 25.6 142.6% View Chart
P/BV x 3.0 3.7 81.2% View Chart
Dividend Yield % 0.8 0.6 130.5%  

Financials

 PIRAMAL ENTERPRISES   SUN PHARMA
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-17
SUN PHARMA
Mar-17
PIRAMAL ENTERPRISES/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs2,095842 248.8%   
Low Rs1,025572 179.1%   
Sales per share (Unadj.) Rs492.8131.6 374.4%  
Earnings per share (Unadj.) Rs72.632.7 221.9%  
Cash flow per share (Unadj.) Rs94.738.0 249.3%  
Dividends per share (Unadj.) Rs21.003.50 600.0%  
Dividend yield (eoy) %1.30.5 272.0%  
Book value per share (Unadj.) Rs862.5152.7 564.8%  
Shares outstanding (eoy) m172.562,399.26 7.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.25.4 58.9%   
Avg P/E ratio x21.521.6 99.4%  
P/CF ratio (eoy) x16.518.6 88.5%  
Price / Book Value ratio x1.84.6 39.1%  
Dividend payout %28.910.7 270.4%   
Avg Mkt Cap Rs m269,1941,696,877 15.9%   
No. of employees `0004.017.5 22.9%   
Total wages/salary Rs m17,93949,023 36.6%   
Avg. sales/employee Rs Th21,190.318,028.3 117.5%   
Avg. wages/employee Rs Th4,470.12,798.8 159.7%   
Avg. net profit/employee Rs Th3,120.04,479.5 69.7%   
INCOME DATA
Net Sales Rs m85,037315,784 26.9%  
Other income Rs m2,3386,232 37.5%   
Total revenues Rs m87,374322,016 27.1%   
Gross profit Rs m34,991100,893 34.7%  
Depreciation Rs m3,81712,648 30.2%   
Interest Rs m20,3103,998 508.0%   
Profit before tax Rs m13,20290,479 14.6%   
Minority Interest Rs m1,6990-   
Prior Period Items Rs m099 0.0%   
Extraordinary Inc (Exp) Rs m-1000-   
Tax Rs m2,28112,116 18.8%   
Profit after tax Rs m12,52078,462 16.0%  
Gross profit margin %41.131.9 128.8%  
Effective tax rate %17.313.4 129.0%   
Net profit margin %14.724.8 59.3%  
BALANCE SHEET DATA
Current assets Rs m87,590329,537 26.6%   
Current liabilities Rs m185,578178,870 103.8%   
Net working cap to sales %-115.247.7 -241.5%  
Current ratio x0.51.8 25.6%  
Inventory Days Days3179 39.3%  
Debtors Days Days4883 57.1%  
Net fixed assets Rs m108,523204,766 53.0%   
Share capital Rs m3452,399 14.4%   
"Free" reserves Rs m148,481363,997 40.8%   
Net worth Rs m148,826366,397 40.6%   
Long term debt Rs m144,95714,361 1,009.4%   
Total assets Rs m482,394614,102 78.6%  
Interest coverage x1.723.6 7.0%   
Debt to equity ratio x1.00 2,485.0%  
Sales to assets ratio x0.20.5 34.3%   
Return on assets %6.813.4 50.7%  
Return on equity %8.421.4 39.3%  
Return on capital %12.024.8 48.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,00144,118 34.0%   
Fx outflow Rs m5,15024,484 21.0%   
Net fx Rs m9,85119,634 50.2%   
CASH FLOW
From Operations Rs m-100,39370,822 -141.8%  
From Investments Rs m-24,202-42,216 57.3%  
From Financial Activity Rs m135,705-22,854 -593.8%  
Net Cashflow Rs m11,1106,107 181.9%  

Share Holding

Indian Promoters % 52.9 63.7 83.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.0 5.1 78.0%  
FIIs % 26.6 23.0 115.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 8.3 198.8%  
Shareholders   93,274 133,026 70.1%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   IPCA LABS  GSK PHARMA  DR. DATSONS LABS  MERCK LTD  NOVARTIS  

Compare PIRAMAL ENTERPRISES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Feb 23, 2018 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 8-QTR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS